These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

687 related items for PubMed ID: 23103794

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model.
    Faivre E, Hölscher C.
    J Alzheimers Dis; 2013; 35(2):267-83. PubMed ID: 23568101
    [Abstract] [Full Text] [Related]

  • 3. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL, Hölscher C.
    Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
    [Abstract] [Full Text] [Related]

  • 4. Neuroprotective effects of D-Ala(2)GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model.
    Faivre E, Hölscher C.
    Alzheimers Res Ther; 2013 Jan; 5(2):20. PubMed ID: 23601582
    [Abstract] [Full Text] [Related]

  • 5. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
    McClean PL, Hölscher C.
    Neuropharmacology; 2014 Nov; 86():241-58. PubMed ID: 25107586
    [Abstract] [Full Text] [Related]

  • 6. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
    Collins JM, King AE, Woodhouse A, Kirkcaldie MT, Vickers JC.
    Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The Novel DA-CH3 Dual Incretin Restores Endoplasmic Reticulum Stress and Autophagy Impairments to Attenuate Alzheimer-Like Pathology and Cognitive Decrements in the APPSWE/PS1ΔE9 Mouse Model.
    Panagaki T, Gengler S, Hölscher C.
    J Alzheimers Dis; 2018 May; 66(1):195-218. PubMed ID: 30282365
    [Abstract] [Full Text] [Related]

  • 9. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease.
    Tai J, Liu W, Li Y, Li L, Hölscher C.
    Brain Res; 2018 Jan 01; 1678():64-74. PubMed ID: 29050859
    [Abstract] [Full Text] [Related]

  • 10. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
    Hansen HH, Fabricius K, Barkholt P, Kongsbak-Wismann P, Schlumberger C, Jelsing J, Terwel D, Termont A, Pyke C, Knudsen LB, Vrang N.
    PLoS One; 2016 Jan 01; 11(7):e0158205. PubMed ID: 27421117
    [Abstract] [Full Text] [Related]

  • 11. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice.
    Gengler S, McClean PL, McCurtin R, Gault VA, Hölscher C.
    Neurobiol Aging; 2012 Feb 01; 33(2):265-76. PubMed ID: 20359773
    [Abstract] [Full Text] [Related]

  • 12. Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice.
    Laursen B, Mørk A, Plath N, Kristiansen U, Bastlund JF.
    Behav Brain Res; 2013 Mar 01; 240():146-52. PubMed ID: 23178660
    [Abstract] [Full Text] [Related]

  • 13. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
    Salles GN, Calió ML, Hölscher C, Pacheco-Soares C, Porcionatto M, Lobo AO.
    Neuropharmacology; 2020 Jan 01; 162():107813. PubMed ID: 31628935
    [Abstract] [Full Text] [Related]

  • 14. The effect of ageing on neurogenesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer's disease.
    Hamilton A, Holscher C.
    Brain Res; 2012 Apr 17; 1449():83-93. PubMed ID: 22418058
    [Abstract] [Full Text] [Related]

  • 15. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
    Hölscher C.
    Biochem Soc Trans; 2011 Aug 17; 39(4):891-7. PubMed ID: 21787319
    [Abstract] [Full Text] [Related]

  • 16. Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice.
    Faivre E, Hamilton A, Hölscher C.
    Eur J Pharmacol; 2012 Jan 15; 674(2-3):294-306. PubMed ID: 22115896
    [Abstract] [Full Text] [Related]

  • 17. Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice.
    McClean PL, Jalewa J, Hölscher C.
    Behav Brain Res; 2015 Oct 15; 293():96-106. PubMed ID: 26205827
    [Abstract] [Full Text] [Related]

  • 18. Chronic treatment with the α2-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APP×PS1 transgenic mice without altering β-amyloid plaque load or astrocytosis.
    Scullion GA, Kendall DA, Marsden CA, Sunter D, Pardon MC.
    Neuropharmacology; 2011 Oct 15; 60(2-3):223-34. PubMed ID: 20850464
    [Abstract] [Full Text] [Related]

  • 19. Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease.
    Cai HY, Yang JT, Wang ZJ, Zhang J, Yang W, Wu MN, Qi JS.
    Biochem Biophys Res Commun; 2018 Jan 01; 495(1):1034-1040. PubMed ID: 29175324
    [Abstract] [Full Text] [Related]

  • 20. Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology.
    Holubová M, Hrubá L, Popelová A, Bencze M, Pražienková V, Gengler S, Kratochvílová H, Haluzík M, Železná B, Kuneš J, Hölscher C, Maletínská L.
    Neuropharmacology; 2019 Jan 01; 144():377-387. PubMed ID: 30428311
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.